Viking Therapeutics financials
$31.81−3.69%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$132.6M | -$164.1M | -$164.7M | -$98.6M | -$74.6M | -$55.5M | -$46.2M | -$36.6M | -$34.1M | -$34.1M | -$29.3M | -$27.3M |
| Net income | -$128.0M | -$158.3M | -$157.7M | -$90.8M | -$65.6M | -$45.6M | -$35.4M | -$24.9M | -$22.3M | -$27.4M | -$24.6M | -$22.5M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-1.10 | $-1.37 | $-1.38 | $-0.81 | $-0.58 | $-0.41 | $-0.32 | $-0.22 | $-0.20 | $-0.26 | $-0.25 | $-0.23 |
| EBITDA | -$132.6M | -$164.1M | -$164.7M | -$98.6M | -$74.6M | -$55.5M | -$46.2M | -$36.6M | -$34.1M | -$34.1M | -$29.3M | -$27.3M |
| Operating cash flow | -$125.2M | -$114.0M | -$85.3M | -$94.0M | -$47.1M | -$52.3M | -$31.2M | -$22.0M | -$28.5M | -$6.1M | -$17.6M | -$19.7M |
| Free cash flow | -$125.2M | -$114.0M | -$85.3M | -$94.0M | -$47.1M | -$52.3M | -$31.2M | -$22.0M | -$28.5M | -$6.1M | -$17.6M | -$19.7M |
| Diluted shares | 116.3M | 115.6M | 114.1M | 112.3M | 112.1M | 112.1M | 111.4M | 110.9M | 110.4M | 103.5M | 100.2M | 99.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $125.8M | $118.1M | $165.8M | $100.4M | $33.9M | $37.9M |
| Short-term investments | $375.9M | $484.8M | $539.9M | $614.2M | $773.8M | $813.9M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $521.9M | $608.2M | $715.7M | $739.4M | $827.9M | $867.0M |
| Total liabilities | $113.6M | $106.3M | $76.7M | $26.4M | $32.4M | $20.1M |
| Shareholders' equity | $408.3M | $501.9M | $639.1M | $713.0M | $795.5M | $846.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology